Register Now: Does Your Pharmaceutical WMS Grow with You?
News|Articles|February 7, 2025

Pharma Pulse 2/7/25: The Impact of AI-Driven Discovery Platforms, Caring for the Caregiver & more

The latest news for pharma industry insiders.

Overall Impact of AI-Driven Discovery Platforms

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI compares and discusses the potential impact of AI-driven drug discovery platforms.

Caring for the Caregiver: Prioritizing Well-Being as a Pharmacist

Pharmacists are essential health care providers, bridging the gap between patients and optimal health outcomes. However, the demands of the profession—long hours, high stress, and emotional strain—can take a toll on their well-being. To sustain their ability to care for others, pharmacists must also care for themselves.

Hims’ Super Bowl Ad Hit for ‘Misleading’ Weight-Loss Claims

A Super Bowl ad touting Hims & Hers Health Inc.’s copycat weight-loss drugs is getting pushback from the branded drugmakers’ lobbying group, which says it’s “misleading” and potentially violates marketing rules.

GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer

GoodRx announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role.

Editor Nicholas Saraceno on LinkedIn

I appreciate the time, Jim! Pharmaceutical Commerce Magazine is dedicated to providing our readers with various buckets of topics - including supply chain - and we'll continue to provide updates on how the tariff news develops.

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs


Related to this article

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.